The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma.
This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that funding will only be available after the NICE recommendation, and not during the interim period between marketing authorisation and NICE recommendation.
For information, this appraisal is now anticipated to begin during early October 2020 when we will write to you about how you can get involved.